Now that the anti-CD38 monoclonal antibodies have shown their potency and usefulness, it seems that EHA 2017 gave us the opportunity to direct our gaze towards the other novel players emerging in the therapeutic field of multiple myeloma (MM). As such, the aim of this article is to focus on some of the earlier phase trials, revealing interesting results concerning potentially potent therapeutic and supportive strategies.

(BELG J HEMATOL 2017;8(4):133–6)